Lucid Diagnostics INC 8-K filings

Lucid Diagnostics announced second quarter 2026 financial results, reporting $1.5 million in revenue and processing 2,770 EsoGuard tests, while also securing a key laboratory benefit manager coverage policy.

Lucid Diagnostics stockholders approved the re-election of directors and an increase in authorized common stock to 400 million shares.

Lucid Diagnostics reported $1.3 million in Q1 2026 revenue from 3,177 EsoGuard tests, bolstered by a $17 million stock offering, extending its cash runway into 2027.

Lucid Diagnostics has successfully closed an underwritten public offering of 18 million shares at $1.00 per share, raising approximately $16.8 million in net proceeds.

Lucid Diagnostics has priced an underwritten public offering of 18 million shares of common stock at $1.00 per share to raise $18 million in gross proceeds.

Lucid Diagnostics announced its fourth quarter and full year 2025 financial results, reporting $1.5 million in Q4 revenue and a significant contract award with the U.S. Department of Veterans Affairs.

Lucid Diagnostics announced its third-quarter 2025 financial results, reporting $1.2 million in EsoGuard revenue and significant progress towards Medicare coverage for its EsoGuard test.

Lucid Diagnostics Inc. announced the appointment of John R. Palumbo, a seasoned healthcare executive, to its Board of Directors, effective September 22, 2025.

Lucid Diagnostics Inc. announced the successful closing of its underwritten public offering, raising approximately $26.9 million for working capital and general corporate purposes.

Lucid Diagnostics Inc. announced the pricing of an underwritten public offering of 25 million shares of common stock at $1.00 per share, aiming to raise $25 million for working capital and general corporate purposes.

Lucid Diagnostics announced its second quarter 2025 financial results, reporting increased revenue and an improved GAAP net loss, alongside a strengthened cash position to extend its operational runway.

Lucid Diagnostics Inc. announced that its stockholders re-elected two Class A directors and approved the issuance of common stock related to its 2024 Senior Secured Convertible Notes, along with ratifying its independent auditor, at the Annual Meeting held on June 18, 2025.

Lucid Diagnostics Inc. has established an at-the-market equity offering program to sell up to $25 million of its common stock, aiming to bolster working capital and support general corporate purposes.

Lucid Diagnostics announced its Q1 2025 financial results, reporting $0.8 million in revenue from 3,034 EsoGuard tests and securing additional capital to extend its operational runway.

Lucid Diagnostics Inc. reports that CBIZ CPAs replaced Marcum LLP as their independent registered public accounting firm following CBIZ CPAs' acquisition of Marcum's attest business.

Lucid Diagnostics successfully closes its public offering, raising approximately $16.1 million for working capital and general corporate purposes.

Lucid Diagnostics announces a public offering of 12.5 million shares of common stock at $1.20 per share, aiming to raise $15 million for working capital and general corporate purposes.

Lucid Diagnostics announced a record number of EsoGuard tests processed in Q4 2024, along with key reimbursement agreements and financial results for the year ended December 31, 2024.

Lucid Diagnostics successfully closes a registered direct offering, raising approximately $15.3 million before expenses.

Lucid Diagnostics has entered into subscription agreements for a $15.3 million registered direct offering of common stock.

Lucid Diagnostics Inc. has terminated its ATM Prospectus Supplement, halting the sale of common stock under the existing offering.

Lucid Diagnostics Inc. has received notification from Nasdaq that it has regained compliance with the $1 minimum bid price requirement for continued listing.

Lucid Diagnostics has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement.

Lucid Diagnostics closed a $21.95 million private placement of convertible notes, using a portion of the proceeds to repay a previous debt of approximately $3.6 million.

Lucid Diagnostics has secured $21.75 million through the sale of Senior Secured Convertible Notes to redeem its existing 2023 Convertible Note.

Lucid Diagnostics announced a 20% sequential increase in EsoGuard test revenue, completed its clinical evidence package for Medicare submission, and secured $21.75 million in funding.

Lucid Diagnostics has entered into a new financing agreement to redeem its existing senior convertible note.

Lucid Diagnostics announced a 31% quarterly increase in EsoGuard test volume and a 44% annual increase, alongside $11.6 million in gross proceeds from a Series B-1 Convertible Preferred Stock issuance.

Lucid Diagnostics Inc. successfully held its annual meeting, re-electing directors, approving the issuance of shares related to recent preferred stock offerings, and increasing the authorized number of common stock shares.

Lucid Diagnostics has received a notice from Nasdaq stating that its share price has fallen below the minimum $1 threshold for continued listing, giving the company 180 days to regain compliance.